The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Mutation

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Mutation.
Marina Chiara Garassino
Connection Strength
2.823
Mutation
  1. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018 08; 13(8):1146-1155.
    View in: PubMed
    Score: 0.266
  2. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. Tumori. 2016 Jun 02; 2016(3):223-5.
    View in: PubMed
    Score: 0.229
  3. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol. 2015 Jul; 16(7):746-8.
    View in: PubMed
    Score: 0.217
  4. Afatinib for lung cancer: let there be light? Lancet Oncol. 2014 Feb; 15(2):133-4.
    View in: PubMed
    Score: 0.197
  5. Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin. J Clin Oncol. 2011 Oct 01; 29(28):3835-7; author reply 3837-9.
    View in: PubMed
    Score: 0.167
  6. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011 Jan; 22(1):235-237.
    View in: PubMed
    Score: 0.160
  7. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2.
    View in: PubMed
    Score: 0.133
  8. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2025 Jan; 199:108051.
    View in: PubMed
    Score: 0.105
  9. Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC. J Thorac Oncol. 2024 Jun; 19(6):877-882.
    View in: PubMed
    Score: 0.101
  10. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
    View in: PubMed
    Score: 0.077
  11. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open. 2020 05; 5(3):e000748.
    View in: PubMed
    Score: 0.076
  12. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.
    View in: PubMed
    Score: 0.073
  13. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
    View in: PubMed
    Score: 0.066
  14. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018 01; 115:135-142.
    View in: PubMed
    Score: 0.065
  15. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori. 2017 Jul 31; 103(4):325-337.
    View in: PubMed
    Score: 0.063
  16. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016 Jun; 468(6):651-62.
    View in: PubMed
    Score: 0.058
  17. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. J Thorac Oncol. 2016 07; 11(7):1170-5.
    View in: PubMed
    Score: 0.058
  18. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015 Oct 06; 6(30):30072-87.
    View in: PubMed
    Score: 0.056
  19. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. 2015 Oct; 26(10):2079-84.
    View in: PubMed
    Score: 0.055
  20. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May; 94(2):213-27.
    View in: PubMed
    Score: 0.052
  21. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des. 2014; 20(24):3933-43.
    View in: PubMed
    Score: 0.049
  22. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 2013 Dec; 8(12):e105-6.
    View in: PubMed
    Score: 0.049
  23. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep; 14(10):981-8.
    View in: PubMed
    Score: 0.048
  24. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res. 2009 Jul; 29(7):2691-701.
    View in: PubMed
    Score: 0.036
  25. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.026
  26. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6.
    View in: PubMed
    Score: 0.025
  27. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
    View in: PubMed
    Score: 0.024
  28. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023 08; 18(8):1031-1041.
    View in: PubMed
    Score: 0.023
  29. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
    View in: PubMed
    Score: 0.023
  30. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
    View in: PubMed
    Score: 0.022
  31. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022 08; 170:41-51.
    View in: PubMed
    Score: 0.022
  32. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer. 2021 10; 160:152-165.
    View in: PubMed
    Score: 0.021
  33. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110.
    View in: PubMed
    Score: 0.021
  34. LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. J Thorac Oncol. 2020 03; 15(3):360-370.
    View in: PubMed
    Score: 0.018
  35. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clin Lung Cancer. 2019 05; 20(3):e413-e417.
    View in: PubMed
    Score: 0.017
  36. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018 Dec 04; 37(1):302.
    View in: PubMed
    Score: 0.017
  37. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709.
    View in: PubMed
    Score: 0.017
  38. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
    View in: PubMed
    Score: 0.016
  39. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handb Exp Pharmacol. 2018; 249:63-89.
    View in: PubMed
    Score: 0.016
  40. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 02 16; 376(7):629-640.
    View in: PubMed
    Score: 0.015
  41. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015 Oct 20; 6(32):34014-22.
    View in: PubMed
    Score: 0.014
  42. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772.
    View in: PubMed
    Score: 0.011
  43. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer. 2011 Mar; 12(2):138-41.
    View in: PubMed
    Score: 0.010
  44. Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.